Products and services
This is a new edition of a book originally published 10 years ago. This is a major revision that updates data supporting the view that psychiatry has been susceptible to fads and fallacies, and that in some ways it continues to make that mistake.
Read More
In 1959, CP Snow could claim that the average intellectual knew about as much about science as his neolithic ancestors. Overstated perhaps, but he had a good point. Science, through its technologies, has crept up to become a dominant explanatory system over the long twentieth century, and yet this has, at least until recently, been largely ignored in the public space.
Read MoreIn relating the story of epilepsy in its modern era. I have used the analogy of the boat journeying through rough seas, buffeted by diverse and independent currents, some medical some scientific, some societal and some personal. It has been an erratic journey, certainly not one like that of an ocean liner taking the shortest […]
Read MoreI am a British neurologist who has practiced in London for over 45 years and specialising in epilepsy (at the ‘National Hospital, Queen Square’, originally called at the National Hospital for the Paralysed and Epileptic).
Read More
What is spirituality, and what does it have to do with psychiatry? These are good questions but not easily answered; they evoke a lot of debate.
Read More
The importance of health systems has been reinforced by the commitment from Low- and Middle-Income Countries (L&MICs) to pursue the target of Universal Health Coverage (UHC), health security, and to achieve the Sustainable Development Goal of Health and Wellbeing [SDG3] and other health related SDGs.
Read More
Chimére Smith is one of tens of millions of Americans with symptoms of long COVID. According to an August 2022 NBC News story, the 40-year-old Black woman from Baltimore was experiencing extreme fatigue, diarrhea, brain fog, and loss of vision in one eye, along with other symptoms. The symptoms were debilitating, preventing Smith from working […]
Read More
The media have been busy in discussion with the results of a large clinical trial that is a new monoclonal antibody therapy, designed to treat patients with the early stages of Alzheimer’s disease. On November 29th, the data was released from the clinical trial, developed by Eisai and Biogen. The outcomes show that the antibody, […]
Read MoreKeep up with the latest from Cambridge University Press on our social media accounts.
